Other · developed by Sunshine Guojian Pharmaceutical Co.
SSGJ-613 is a drug given by subcutaneous injection in a trial in gout arthritis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07708181 | Phase 2 | Gout Arthritis | Not yet recruiting | SBFM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Gout Arthritis
Updated Nov 1, 2026. Something wrong or missing? Report it on the SBFM page.
See SBFM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SBFM catalysts and pipeline →